ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.25 +0.08 (+0.40%)

Delayed Quote Updated: 2:20 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022

April 21, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis ↗

April 19, 2022

Via Benzinga

Futures Flat As Yen Discombobulation Extends To Record 13th Day ↗

April 19, 2022

After some jerky rollercoaster moves in Monday's illiquid trading session, which jerked both higher and lower before closing modestly in the green.

Via Talk Markets

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

April 19, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗

April 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 19, 2022

Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

23 Stocks Moving in Tuesday's Pre-Market Session ↗

April 19, 2022

Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS...

Via Benzinga

Why Acadia Pharma Shares Are Falling Today ↗

April 19, 2022

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 18, 2022

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.

Via Benzinga

Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain

April 18, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

28 Biggest Movers From Yesterday ↗

April 12, 2022

Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire...

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Acadia: Helping With Alzheimers And Parkinsons ↗

April 03, 2022

Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia...

Via Talk Markets

Stocks And Oil Drop Following The Weak Job Report ↗

March 30, 2022

It was a strange day for the market that started with a big miss on the ADP job report.

Via Talk Markets

9 Monster Stock Market Predictions For The Week Of March 28 ↗

March 27, 2022

It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the...

Via Talk Markets

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

March 22, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today ↗

March 16, 2022

We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about!

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗

March 16, 2022

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...

Via Benzinga

A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision ↗

March 16, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results...

Via Benzinga

Expert Ratings For ACADIA Pharmaceuticals ↗

March 03, 2022

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks...

Via Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings ↗

February 28, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis ↗

February 16, 2022

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated...

Via Benzinga

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

February 16, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

February 14, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

February 11, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.